The Food and Drug Administration on Monday approved Genentech's drug Tecentriq to treat advanced bladder cancer.
The immunotherapy drug first earned FDA approval to treat urothelial carcinoma — the most common type of bladder cancer — in May 2016. The FDA also approved the drug as a second-line treatment for metastatic non-small cell lung cancer in October 2016.
Tecentriq can now be used to treat patients with advanced bladder cancer who are not eligible for standard chemotherapy, according to the report.
More articles on supply chain:
Medtronic sells majority of medical supplies unit to Cardinal for $6.1B
Bristol-Myers will license drugs to Biogen, Roche for $470M
FDA rejects Eli Lilly's arthritis drug